



Ref. No.: EIKO/BSE/2021-22/33

Dated: 08.02.2022

To,
Corporate Services Department,
BSE Limited, P J Towers,
1st Floor, Dalal Street,
Fort, Mumbai - 400001.
BSE Scrip Code: EIKO 540204

Sub: Outcome of the Board Meeting held today i.e., February 08, 2022

Ref: Eiko Lifesciences Limited

BSE Scrip Code: EIKO 540204

Dear Sir,

Pursuant to Reg. 30, 33 and other applicable regulations of the SEBI (LODR) Regulations, 2015, the Board of Directors of the Company, at their meeting held today i.e., February 08, 2022. (Meeting commenced at 4.00 p.m. and concluded at 4.25 P.M) considered, approved, and taken on record the following:

1. Unaudited financial results of the Company for the quarter and nine months ended December 31, 2021.
2. Limited Review Report issued by the Statutory Auditors for quarter and nine months ended December 31, 2021.
3. Resignation of Mr. Tejas Arun Deherkar, Chief Financial Officer and Key Managerial Personnel with effect from the close of business hours on February 08, 2022.
4. Appointment of Mr. Jaid Ismail Kojar, as Chief Financial Officer and Key Managerial Personnel of the Company with effect from the start of business hours on February 09, 2022.



Further, Pursuant to the Regulation 33 of the Listing Regulations, we are enclosing herewith a copy of the Unaudited Financial Results and Limited Review Report of the Statutory Auditors of the Company.

The said results shall be published in one English and one vernacular newspaper as required.

Further, the details/disclosures required under Regulation 30 of the SEBI Listing Regulations, read with Schedule III thereto and the SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015 (“SEBI Circular”), is enclosed herewith as Annexure.

Further, with reference to our letter dated December 30, 2021, please note the trading window for dealing in the securities of the Company by the Insiders, as defined under the SEBI (Prohibition of Insider Trading) Regulations, 2015 shall re-open from Friday, February 11, 2022.

Please take the same on your records.

Thanking you.

For **EIKO LIFESCIENCES LIMITED**

Avi Mundecha
Company Secretary
ACS-65529

Encl.: As above.



ANNEXURE

A. Cessation of Mr. Tejas Arun Deherkar, Chief Financial Officer and Key Managerial Personnel of the Company with effect from the close of business hours on February 08, 2022.

Sr. No.	Particulars	Details
1.	Reason for change e viz. appointment , resignation, removal , death or otherwise;	Resignation of Mr. Tejas Arun Deherkar from the service of the Company due to personal reason
2.	Date of appointment /cessation (as applicable) & term of appointment	With effect from close of business hours on February 08, 2022

B. Appointment of Mr. Jaid Ismail Kojar as the new Chief Financial Officer and Key Managerial Personnel of the Company with effect from the start of business hours on February 09, 2022

Sr. No.	Particulars	Details
1.	Reason for change e viz. appointment , resignation, removal , death or otherwise;	Appointment of Mr. Jaid Ismail Kojar, as the new Chief Financial Officer and a Key Managerial Personnel of the Company, after resignation of Mr. Tejas Arun Deherkar from the close of business hours on February 08, 2022
2.	Date of appointment /cessation (as applicable) & term of appointment	With effect from start of business hours on February 09, 2022
3.	Brief profile (in case of appointment);	Mr. Jaid Ismail Kojar is Commerce graduate from Mumbai University, Maharashtra having rich experience of more than 13 years in varied fields including accounting and Finance Management.

UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER 2021

(Amount in Lakhs)

Sr. No.	Particulars	Quarter ended			Nine Months Ended		Year ended
		31.12.2021	30.09.2021	31.12.2020	31.12.2021	31.12.2020	31.03.2021
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Revenue from operations	558.04	609.43	584.59	2,012.00	584.59	1,199.06
	Other income	14.72	19.43	12.16	46.80	32.34	46.03
	Total revenue	572.76	628.86	596.75	2,058.80	616.93	1,245.08
2	Expenses						
	Cost of material consumed	727.61	597.03	547.76	2,091.06	547.76	1,066.60
	Changes in inventories of finished stock and work-in-progress	(216.69)	(57.17)	-	(299.43)	-	(5.40)
	Employee benefits expense	9.44	5.19	3.68	23.27	8.89	11.83
	Depreciation and amortization expense	15.26	16.06	1.54	40.60	4.62	6.16
	Finance Cost	12.67	18.57	2.09	35.79	3.23	8.78
	Other expenses	32.33	19.93	14.00	92.50	17.71	73.85
	Total expenses	580.63	599.60	569.07	1,983.80	582.21	1,161.81
3	Profit/(Loss) from ordinary activities before tax	(7.87)	29.26	27.69	75.00	34.73	83.27
4	Tax expense:						
	(1) Current tax	(7.56)	1.80	7.04	-	8.94	22.08
	(2) Earlier year's Tax	-	0.25	0.03	0.25	0.03	0.03
	(4) Deferred tax	5.81	5.34	(0.07)	18.87	(0.20)	(0.27)
5	Profit/(Loss) from ordinary activities after tax	(6.12)	21.88	20.69	55.88	25.96	61.43
6	Other Comprehensive Income (OCI)	-	-	-	-	-	-
	<u>Item that will not be reclassified to profit or loss</u>	-	-	-	-	-	-
	Gain/(Loss) on recognised on fair valuation of Financial Assets	(3.36)	(1.24)	4.90	(4.66)	9.55	11.99
	Income tax relating to these items	0.85	0.31	(1.23)	1.17	(2.40)	(3.02)
	Total Other Comprehensive Income (OCI)	(2.52)	(0.93)	3.67	(3.49)	7.14	8.98
	Profit/(Loss) for the Period	(8.64)	20.95	24.35	52.39	33.10	70.41
	Paid up Equity Share Capital (Face Value of Rs. 10 each)	831.63	831.63	382.00	831.63	382.00	382.00
7	Earnings Per Share (EPS) (Not annualised)						
	(1) Basic	(0.07)	0.26	0.54	0.73	0.68	1.61
	(2) Diluted	(0.07)	0.26	0.54	0.73	0.68	1.61




Notes:

1. The above Financial Results for the quarter and nine months ended 31st December 2021 have been reviewed and recommended by Audit Committee and has been approved by the Board of Directors at its Meeting held on Tuesday, 08th February 2022. The Statutory Auditors have carried out Limited Review of above results and expressed an unmodified opinion on these financial results.
2. The Company has single business segment namely "**Speciality & Fine Chemicals**" therefore in the context of Ind As 108, disclosure of segment information is not applicable.
3. Raw Material consumption includes **₹28.67 Lakhs** on account of development of new molecules for Agrochemical Intermediates, Polymer Science and Pharma segment. Company has successfully developed these molecules and have also launched the same during the last quarter and looking forward for substantial incremental business opportunities in the following quarters.
4. Previous quarter figures have been regrouped reclassified wherever necessary, to make them comparable.

For Eiko Lifesciences Limited

L.K. Kabra

Laxmikant Kabra
Director
DIN: 00061346



Place: Thane
Dated: 8th February 2022



Independent Auditor's Review Report on the Unaudited Quarterly and Nine Months Ended Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors
EIKO LIFESCIENCES LIMITED

1. We have reviewed the accompanying statement of unaudited financial results of EIKO LIFESCIENCES LIMITED (the "Company") for the Quarter and Nine Months ended December 31, 2021 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial result prepared in accordance with applicable Principles laid down in Indian Accounting Standards 34 "Interim Financial Reporting" ("Ind AS 34") prescribed under section 133 of companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015 read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement

For Thanawala & Company
Chartered Accountants
Firm Reg. No.: 110948W


CA Vijay Thanawala
Proprietor
Membership No.: 015532



Place: Mumbai
Date: 8th February 2022

UDIN: 22015632AAVYIH2048